Phathom Pharmaceuticals (PHAT) Stock
Biotech company developing medicines for digestive disorders. Here's the price, business snapshot, and what's worth knowing about Phathom Pharmaceuticals in June 2026.
Phathom Pharmaceuticals Inc (PHAT) is a clinical-stage pharmaceutical company focused on developing novel therapeutics, with an emphasis on gastrointestinal disorders and other indications. Investors should know the company’s near-term value is typically driven by clinical-trial readouts, regulatory milestones and partnership activity. With a market capitalisation around $993.21 million, Phathom sits in the mid-cap biotech space where share prices can be volatile and sensitive to binary events. Clinical-stage firms often do not have steady revenues and may require additional financing, so cash runway and upcoming catalysts are key to monitor. Upside can come from positive data or regulatory approvals, while downside stems from trial failures, delays and competitive developments. This summary is for general educational purposes only and not personalised advice; investors should consider their own risk tolerance and consult a financial professional before making decisions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Phathom Pharmaceuticals' stock with a target price of $23.27, indicating strong growth potential.
Financial Health
Phathom Pharmaceuticals is performing well, generating strong revenue and cash flow with healthy profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring PHAT
Beyond The Patent Cliff: Pharma's New Growth Engines
AbbVie raised its profit outlook, proving it can thrive after its blockbuster Humira faced competition. This creates an investment opportunity in resilient pharmaceutical companies that are successfully launching new drugs to replace older ones.
Published: 1 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts Ahead
Clinical readouts and regulatory milestones can be major value drivers, though outcomes are binary and can cause volatility.
Volatility & Opportunity
Mid-cap biotech status means share moves can be large on news; potential upside exists but so does downside risk.
Funding & Runway
Watch cash runway, financing plans and partnerships—funding needs can dilute shareholders and affect strategic options.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
